{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:16:07Z","timestamp":1771989367306,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30GM127607"],"award-info":[{"award-number":["P30GM127607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.taap.2023.116791","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T17:14:02Z","timestamp":1702574042000},"page":"116791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recent advances in the cardiotoxicity of anti-cancer drugs: Navigating the landscape of anthracycline-induced cardiotoxicity"],"prefix":"10.1016","volume":"482","author":[{"given":"Mark","family":"Chandy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"Conklin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116791_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116362","article-title":"Upcycling the anthracyclines: new mechanisms of action, toxicology, and pharmacology","volume":"459","author":"Bayles","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116411","article-title":"Ring finger protein 10 improves pirarubicin-induced cardiac inflammation by regulating the AP-1\/Meox2 signaling pathway","volume":"462","author":"Duan","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116609","article-title":"D-limonene complexed with cyclodextrin attenuates cardiac arrhythmias in an experimental model of doxorubicin-induced cardiotoxicity: possible involvement of calcium\/calmodulin-dependent protein kinase type II","volume":"474","author":"Durco","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116405","article-title":"Natural bioactive compounds-doxorubicin combinations targeting topoisomerase II-alpha: anticancer efficacy and safety","volume":"461","author":"Elfadadny","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116210","article-title":"Differential impact of doxorubicin dose on cell death and autophagy pathways during acute cardiotoxicity","volume":"453","author":"Kawalec","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116531","article-title":"The chemotherapeutic drug doxorubicin does not exacerbate p16(Ink4a)-positive senescent cell accumulation and cardiometabolic disease development in young adult female LDLR-deficient mice","volume":"468","author":"Postmus","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116687","article-title":"Afzelin protects against doxorubicin-induced cardiotoxicity by promoting the AMPKalpha\/SIRT1 signaling pathway","volume":"477","author":"Sun","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116547","article-title":"TRPC6 promotes daunorubicin-induced mitochondrial fission and cell death in rat cardiomyocytes with the involvement of ERK1\/2-DRP1 activation","volume":"470","author":"Xu","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.116179","article-title":"Ononin alleviates endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity by activating SIRT3","volume":"452","author":"Zhang","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116412","article-title":"GSK2795039 prevents RIP1-RIP3-MLKL-mediated cardiomyocyte necroptosis in doxorubicin-induced heart failure through inhibition of NADPH oxidase-derived oxidative stress","volume":"463","author":"Zhang","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2023.116791_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116448","article-title":"Potential cardioprotective and anticancer effects of carvedilol either free or as loaded nanoparticles with or without doxorubicin in solid Ehrlich carcinoma-bearing mice","volume":"465","author":"Zidan","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23004301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23004301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:06:56Z","timestamp":1758575216000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23004301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":11,"alternative-id":["S0041008X23004301"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116791","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in the cardiotoxicity of anti-cancer drugs: Navigating the landscape of anthracycline-induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116791","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116791"}}